Revenue
No reported data
Kairos Pharma, LTD. (KAPA)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $2.1M | $414,000 | $82,000 |
| Operating expenses | $5.6M | $2.3M | $1.7M |
| Operating income | −$5.6M | −$2.3M | −$1.7M |
| Net income | −$5.4M | −$2.6M | −$1.8M |
| Basic EPSper diluted share | -$0.30 | -$0.23 | -$0.17 |
| Diluted EPSper diluted share | -$0.30 | -$0.23 | -$0.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 25, 2024Form 4 | Murali RamachandranVP of Research and Development | BuyCOMMON STOCK | 200 | $1.59 | $318.00 | 133.1K |
| Nov 22, 2024Form 4 | Samuelson DougChief Financial Officer | BuyCOMMON STOCK | 2.5K | $1.50 | $3.8K | 60.8K |
| Nov 20, 2024Form 4 | Yu John SCEO and Chairman | BuyCOMMON STOCK | 4.0K | $1.44 | $5.8K | 5.34M |